264 related articles for article (PubMed ID: 34733290)
1. DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor.
Wang C; Zainal NS; Chai SJ; Dickie J; Gan CP; Zulaziz N; Lye BKW; Sutavani RV; Ottensmeier CH; King EV; Abraham MT; Ismail SMB; Lau SH; Kallarakkal TG; Mun KS; Zain RB; Abdul Rahman ZA; Thomas GJ; Cheong SC; Savelyeva N; Lim KP
Front Immunol; 2021; 12():763086. PubMed ID: 34733290
[TBL] [Abstract][Full Text] [Related]
2. Personalized cancer vaccination in head and neck cancer.
Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of dual-antigenic PV1 peptide vaccine in head and neck cancer patients.
Chai SJ; Fong SCY; Gan CP; Pua KC; Lim PVH; Lau SH; Zain RB; Abraham T; Ismail SM; Abdul Rahman ZA; Ponniah S; Patel V; Cheong SC; Lim KP
Hum Vaccin Immunother; 2019; 15(1):167-178. PubMed ID: 30193086
[TBL] [Abstract][Full Text] [Related]
4. Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck.
Zandberg DP; Menk AV; Velez M; Normolle D; DePeaux K; Liu A; Ferris RL; Delgoffe GM
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986123
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
Kono M; Saito S; Rokugo M; Egloff AM; Uppaluri R
Oral Oncol; 2024 May; 152():106795. PubMed ID: 38599127
[TBL] [Abstract][Full Text] [Related]
6.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
7. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.
Tan YS; Sansanaphongpricha K; Xie Y; Donnelly CR; Luo X; Heath BR; Zhao X; Bellile E; Hu H; Chen H; Polverini PJ; Chen Q; Young S; Carey TE; Nör JE; Ferris RL; Wolf GT; Sun D; Lei YL
Clin Cancer Res; 2018 Sep; 24(17):4242-4255. PubMed ID: 29769207
[No Abstract] [Full Text] [Related]
8. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
[TBL] [Abstract][Full Text] [Related]
9. Head and Neck Cancer Immunotherapy beyond the Checkpoint Blockade.
Heath BR; Michmerhuizen NL; Donnelly CR; Sansanaphongpricha K; Sun D; Brenner JC; Lei YL
J Dent Res; 2019 Sep; 98(10):1073-1080. PubMed ID: 31340724
[TBL] [Abstract][Full Text] [Related]
10. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
[TBL] [Abstract][Full Text] [Related]
12. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
13. HNSCC: Tumour Antigens and Their Targeting by Immunotherapy.
von Witzleben A; Wang C; Laban S; Savelyeva N; Ottensmeier CH
Cells; 2020 Sep; 9(9):. PubMed ID: 32942747
[TBL] [Abstract][Full Text] [Related]
14. Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.
Li L; Zhang X; Wang X; Kim SW; Herndon JM; Becker-Hapak MK; Carreno BM; Myers NB; Sturmoski MA; McLellan MD; Miller CA; Johanns TM; Tan BR; Dunn GP; Fleming TP; Hansen TH; Goedegebuure SP; Gillanders WE
Genome Med; 2021 Apr; 13(1):56. PubMed ID: 33879241
[TBL] [Abstract][Full Text] [Related]
15. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma.
Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014
[TBL] [Abstract][Full Text] [Related]
17. Targeting Dendritic Cell Dysfunction to Circumvent Anti-PD1 Resistance in Head and Neck Cancer.
Saito S; Kono M; Nguyen HCB; Egloff AM; Messier C; Lizotte P; Paweletz C; Adkins D; Uppaluri R
Clin Cancer Res; 2024 May; 30(9):1934-1944. PubMed ID: 38372707
[TBL] [Abstract][Full Text] [Related]
18. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial.
Weed DT; Zilio S; Reis IM; Sargi Z; Abouyared M; Gomez-Fernandez CR; Civantos FJ; Rodriguez CP; Serafini P
Front Immunol; 2019; 10():1206. PubMed ID: 31214178
[TBL] [Abstract][Full Text] [Related]
19. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
